Mare Nishiura1, Atsuhisa Tamura2, Hideaki Nagai2, Eisuke Matsushima1. 1. Section of Liaison,Psychiatry and Palliative Medicine,Graduate School of Medical and Dental Sciences,Tokyo Medical and Dental University,Bunkyo-ku,Tokyo,Japan. 2. Center for Pulmonary Diseases,National Hospital Organization,Tokyo National Hospital,Kiyose-shi,Tokyo,Japan.
Abstract
OBJECTIVE: We investigated the prevalence of sleep disturbance and psychological distress in lung cancer patients. We also examined the association between sleep disturbance and psychological distress, pain, fatigue, and quality of life in the same population. METHOD: Fifty lung cancer patients were evaluated. Sleep disturbance was assessed using the Athens Sleep Insomnia Scale (AIS) and psychological distress using the Hospital Anxiety and Depression Scale (HADS). Quality of life (QOL), pain, and fatigue were assessed employing the European Organization of Research and Treatment Quality of Life Questionnaire-Cancer 30 (EORTC QLQ-C30). RESULTS: We observed that 56% of lung cancer patients had sleep disturbance (AIS score ≥6) and 60% had psychological distress (total HADS score ≥11). Patients with sleep disturbance had a HADS score of 14.6 ± 5.8, a fatigue score of 45.3 ± 22.0, and a pain score of 27.2 ± 26.2. In contrast, patients without sleep disturbance had a lower HADS score of 9.9 ± 8.1 (p < 0.05) and a higher fatigue score of 28.5 ± 18.0 (p < 0.01) and a pain score of 8.7 ± 15.8 (p < 0.01). In addition, we found a lower QOL in patients with sleep disturbance (46.3 ± 20.2) than in those without (65.2 ± 20.7) (p < 0.05). We also observed a significant correlation between the AIS, HADS, fatigue, QOL, and pain scores. SIGNIFICANCE OF RESULTS: Lung cancer patients suffered from combined symptoms related to sleep. Sleeping pills improved sleep induction but were not sufficient to provide sleep quality and prevent daytime dysfunction. Daytime dysfunction was specifically associated with psychological distress. Additionally, the type of sleep disturbance was related to other patient factors, including whether or not they received chemotherapy.
OBJECTIVE: We investigated the prevalence of sleep disturbance and psychological distress in lung cancerpatients. We also examined the association between sleep disturbance and psychological distress, pain, fatigue, and quality of life in the same population. METHOD: Fifty lung cancerpatients were evaluated. Sleep disturbance was assessed using the Athens Sleep Insomnia Scale (AIS) and psychological distress using the Hospital Anxiety and Depression Scale (HADS). Quality of life (QOL), pain, and fatigue were assessed employing the European Organization of Research and Treatment Quality of Life Questionnaire-Cancer 30 (EORTC QLQ-C30). RESULTS: We observed that 56% of lung cancerpatients had sleep disturbance (AIS score ≥6) and 60% had psychological distress (total HADS score ≥11). Patients with sleep disturbance had a HADS score of 14.6 ± 5.8, a fatigue score of 45.3 ± 22.0, and a pain score of 27.2 ± 26.2. In contrast, patients without sleep disturbance had a lower HADS score of 9.9 ± 8.1 (p < 0.05) and a higher fatigue score of 28.5 ± 18.0 (p < 0.01) and a pain score of 8.7 ± 15.8 (p < 0.01). In addition, we found a lower QOL in patients with sleep disturbance (46.3 ± 20.2) than in those without (65.2 ± 20.7) (p < 0.05). We also observed a significant correlation between the AIS, HADS, fatigue, QOL, and pain scores. SIGNIFICANCE OF RESULTS:Lung cancerpatients suffered from combined symptoms related to sleep. Sleeping pills improved sleep induction but were not sufficient to provide sleep quality and prevent daytime dysfunction. Daytime dysfunction was specifically associated with psychological distress. Additionally, the type of sleep disturbance was related to other patient factors, including whether or not they received chemotherapy.
Authors: Sally A D Romero; Eileen Jiang; Jason Bussell; Whitney Eriksen; Katherine N Duhamel; Frances K Barg; Jun J Mao Journal: Palliat Support Care Date: 2020-06
Authors: Cari Davies; Stephen Lloyd Brown; Peter Fisher; Laura Hope-Stone; Debra Fisher; Andrew Morgan; Mary Gemma Cherry Journal: Eye (Lond) Date: 2022-08-08 Impact factor: 4.456
Authors: Sebastiano Mercadante; Claudio Adile; Patrizia Ferrera; Francesco Masedu; Marco Valenti; Federica Aielli Journal: Support Care Cancer Date: 2016-12-13 Impact factor: 3.603
Authors: Sheila N Garland; Kelly Trevino; Kevin T Liou; Philip Gehrman; Eugenie Spiguel; Jodi MacLeod; Desirée A H Walker; Betsy Glosik; Christina Seluzicki; Frances K Barg; Jun J Mao Journal: J Cancer Surviv Date: 2021-02-19 Impact factor: 4.442
Authors: Dirk Rades; Svenja Kopelke; Soeren Tvilsted; Troels W Kjaer; Steven E Schild; Tobias Bartscht Journal: In Vivo Date: 2021 Nov-Dec Impact factor: 2.155
Authors: Anna Renom-Guiteras; José Planas; Cristina Farriols; Sergi Mojal; Ramón Miralles; Maria A Silvent; Ada I Ruiz-Ripoll Journal: BMC Palliat Care Date: 2014-08-12 Impact factor: 3.234